Scoopfeeds — Intelligent news, curated.
The FDA just approved a new depression treatment—and it doesn’t involve medication
business

The FDA just approved a new depression treatment—and it doesn’t involve medication

Fast Company · Jun 12, 2026, 8:00 AM

Would you zap your brain to treat depression? In December, the Food and Drug Administration cleared a device that uses mild electrical currents to stimulate the brain, marking a shift in how the condition could be treated. Known as transcranial direct-current stimulation, or t DCS, the technology is designed for at-home use, potentially offering a more accessible alternative to traditional therapies, according to The New York Times. The approval applies to a headset made by Swedish company Flow Neuroscience, which has been studying the approach for years. While tDCS itself has existed for more than two decades and has been available in England since 2019, the FDA’s decision gives the treatment new legitimacy in the U.S., where it had largely existed on the fringes of wellness products. “It legitimizes the therapy itself as a medical therapy, and not just something sold online for wellness or enhancement,” Anna Wexler, an assistant professor of medical ethics at the University of Pennsylvania who studies do-it-yourself brain stimulation, told the Times. The device works by delivering a weak electrical current to the brain, lowering the threshold for neurons to fire and potentially improving communication between brain regions. That approach reflects a broader shift in how scientists understand depression, as not just a chemical imbalance, but as a disorder tied to disrupted neural connectivity. For decades, treatment has centered on selective serotonin reuptake inhibitors, or SSRIs, which became dominant in the late 1980s. Today, roughly one in six Americans takes an antidepressant, according to a report. But some researchers say tools like tDCS could push psychiatry beyond its reliance on medication. “Our brains are so pharmaceutically inclined,” Mark George, of the Medical University of South Carolina, where he is a leading expert in neuromodulation, told the Times. Rather than altering brain chemistry as medication does, the device directly stimulates neural activi

Article preview — originally published by Fast Company. Full story at the source.
Read full story on Fast Company → More top stories
Aggregated and edited by the Scoop newsroom. We surface news from Fast Company alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop